美国与加拿大HIV感染者启动ART后INSTI与TAF相关体重增加研究
该研究分析北美2007-2021年启动ART的初治成人,发现INSTI和PI较非EFV的NNRTI体重增加更多,INSTI中比克替拉韦最高,TAF联合INSTI者体重增加高于TDF,黑人女性使用比克替拉韦或多替拉韦联合TAF时2年体重增加最高。
要点
- INSTI和PI的2年平均预测体重增加高于非EFV的NNRTI。
- INSTI中比克替拉韦体重增加数值最高,依次为多替拉韦、拉替拉韦、艾维雷韦。
- 黑人女性使用比克替拉韦或多替拉韦联合TAF时2年体重增加最高。
核心结论
- 非EFV的NNRTI体重增加低于PI和INSTI,黑人女性启动TAF联合当代INSTI者体重增加最大。
主要发现
- 2年时INSTI平均预测体重增加4.9 kg(95% CI: 4.6-5.2),PI为4.7 kg(95% CI: 4.4-5.1),非EFV的NNRTI为2.7 kg(95% CI: 2.4-2.9)。
- 限制于含TDF方案并排除EFV后差异仍存在。
- INSTI中比克替拉韦平均预测体重增加6.9 kg(95% CI: 5.8-7.9),多替拉韦5.3 kg(95% CI: 4.8-5.9),拉替拉韦4.5 kg(95% CI: 3.8-5.3),艾维雷韦4.0 kg(95% CI: 3.6-4.5)。
- TAF联合INSTI者体重增加高于TDF联合INSTI者。
- 黑人女性使用比克替拉韦或多替拉韦联合TAF时2年体重增加10.0 kg(95% CI: 7.4-12.6)。
临床怎么用
- 启动ART时应考虑INSTI和TAF对体重的影响,尤其对黑人女性等高风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Weight gain is common following antiretroviral therapy (ART) initiation. Integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF) have been associated with greater weight gain, though prior analyses may have been confounded by the weight-suppressive effects of efavirenz (EFV) and tenofovir disoproxil fumarate (TDF). METHODS: Treatment-naive adults in the North American AIDS Cohort Collaboration on Research and Design initiating ART between 2007 and 2021 were analyzed. Predicted weight change was modeled using linear mixed effects models adjusted for demographic and clinical factors, and nucleoside reverse transcriptase inhibitor (NRTI) backbone, with subanalyses excluding EFV and stratifying by INSTI agent, NRTI, sex, and race. RESULTS: A total of 32 514 persons were included. At 2 years, INSTIs (4.9 kg, 95% CI: 4.6-5.2) and protease inhibitors (PIs) (4.7 kg, 95% CI: 4.4-5.1) were associated with greater mean predicted weight gain compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (2.7 kg, 95% CI: 2.4-2.9). Differences persisted when limiting analyses to TDF-containing regimens and excluding EFV. Among INSTIs, mean predicted weight gain was numerically highest with bictegravir (6.9 kg, 95% CI: 5.8-7.9), followed by dolutegravir (5.3 kg, 95% CI: 4.8-5.9), raltegravir (4.5 kg, 95% CI: 3.8-5.3), and elvitegravir (4.0 kg, 95% CI: 3.6-4.5). Participants receiving TAF with INSTIs gained more than those on TDF. Black females on bictegravir or dolutegravir with TAF had the highest gain at 2 years (10.0 kg, 95% CI: 7.4-12.6). CONCLUSIONS: Weight gain with non-EFV NNRTIs was lower than with PIs and INSTIs, with the greatest increases observed among Black females starting TAF with contemporary INSTIs.
引用
- Bourgi K, Bian A, Boyd L, et al. Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada. J Infect Dis. 2026. PMID: 42216675. doi:10.1093/infdis/jiag271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。